Where evidence is strongest
The most substantial human record concerns pediatric growth-hormone deficiency and a defined prescription-drug context. Those studies do not establish broad adult anti-aging outcomes.
How to read current claims
- Separate pediatric growth evidence from adult surrogate-marker studies.
- Separate historical regulated product evidence from current compounded or research products.
- Do not treat increased IGF-1 as proof of broad clinical benefit.
Historical evidence has a defined population and product context
The 1996 multicenter study enrolled 110 children with growth-hormone deficiency and evaluated a historical daily GHRH(1-29) protocol. It was open label and addressed a defined pediatric setting. That record cannot be broadened into evidence for adult anti-aging, weight loss, modern clinic blends, oral products, or current research-vendor vials.
A historical pediatric comparison also found that the studied interventions were not equivalent in growth response. Mechanistic resemblance and shared endocrine pathways do not establish interchangeable clinical outcomes.
How to interpret the regulatory history
FDA's orphan record documents Geref marketing approval in 1997 for a defined pediatric indication. That is meaningful historical regulatory evidence for a specific product and use. It does not attach the historical approval to every product sold under the Sermorelin name today.
Current market or withdrawal status needs a fresh authoritative regulatory record before the page makes a detailed present-tense claim. The absence of that verified update is recorded as unknown, not filled with a prediction or a secondary marketing summary.
Surrogate endocrine outcomes are not broad benefit claims
Adult research can report endocrine or metabolic measurements, but a change in a surrogate marker does not by itself establish longer life, fat loss, improved recovery, or general anti-aging benefit. Each outcome must stay tied to the exact population, product, route, study design, and time period in which it was measured.
What this evidence review covers
Explain historical Sermorelin/GHRH(1-29) evidence and regulatory history without extending it to modern anti-aging, weight-loss, oral, or research-product claims.
- What Sermorelin/GHRH(1-29) is
- Historical pediatric multicenter study
- Historical comparison with growth hormone
- Older-adult GHRH study with narrow population limits
- Geref regulatory history
- Current research-product identity gap
- Held claims: weight loss, oral supplement, anti-aging, provider review, combination use
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
historical direct human evidence
The 1996 multicenter open-label study enrolled 110 growth-hormone-deficient children and evaluated a historical daily GHRH(1-29) protocol.
historical comparative evidence
A historical pediatric comparison found the interventions were not equivalent in growth response.
historical regulatory
FDA's orphan record documents Geref marketing approval in 1997 for a defined pediatric indication.
source limitation
These sources do not establish present-day weight-loss, anti-aging, oral-product, or current vendor equivalence claims.
| Evidence class | What the source supports |
|---|---|
| historical direct human evidence | The 1996 multicenter open-label study enrolled 110 growth-hormone-deficient children and evaluated a historical daily GHRH(1-29) protocol. |
| historical comparative evidence | A historical pediatric comparison found the interventions were not equivalent in growth response. |
| historical regulatory | FDA's orphan record documents Geref marketing approval in 1997 for a defined pediatric indication. |
| source limitation | These sources do not establish present-day weight-loss, anti-aging, oral-product, or current vendor equivalence claims. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
GHRH(1-29) therapy in growth-hormone-deficient children
Evidence class: primary open label multicenter historical. What it supports: Historical n=110 pediatric regulated-product protocol, growth-velocity outcomes, and reported short-term safety measures.
What it does not establish: Adult anti-aging, weight loss, current research-vendor products, or a modern self-treatment dose.
Growth hormone versus GHRH(1-29) in children with growth-hormone deficiency
Evidence class: primary historical comparative study. What it supports: A historical pediatric comparison and the fact that the interventions were not equivalent.
What it does not establish: Present-day product equivalence or adult-use claims.
FDA orphan designation and marketing-approval record for Geref
Evidence class: primary regulatory historical. What it supports: The historical regulated-product approval record and approved pediatric context.
What it does not establish: Current market availability or equivalence of products labeled sermorelin by research vendors.
Long-term GHRH(1-29) in age-advanced adults
Evidence class: primary historical human study. What it supports: Historical endocrine and metabolic observations in a defined older-adult study.
What it does not establish: Current anti-aging, bodybuilding, weight-loss, or research-product claims.
Questions this page answers
Was Sermorelin ever FDA approved?
The inspected FDA orphan record shows historical Geref approval in 1997 for a defined pediatric indication; the page must not imply a current research vial shares that approval.
Does Sermorelin cause weight loss?
The core historical sources do not establish a modern weight-loss indication or outcome claim.
Is oral Sermorelin equivalent to the studied product?
No equivalence evidence was identified; route and product identity differ.
Can Sermorelin be compared with tesamorelin or CJC-1295?
Only with a dedicated source packet for each exact molecule, population, product, and status. Do not answer from class resemblance alone.
What remains unresolved
- Current Geref market/withdrawal status requires a fresh authoritative regulatory record before detailed claims.
- No evidence packet for modern clinic blends or oral products.
- Adult anti-aging and weight-loss claims are unsupported by the core sources.
- Tesamorelin/CJC comparisons need dedicated route ownership or should remain held.